Utilizing EndoPAT Device for Endothelial Dysfunction Assessment in Erectile Dysfunction and Hormonal Therapy

What this Trial Is About

Researchers are studying endothelial dysfunction in men aged 30 to 50 who have vasculogenic erectile dysfunction (ED) confirmed by penile Doppler ultrasound. The study also investigates changes in endothelial function in men with hypogonadism before and after they begin testosterone therapy. The research aims to better understand how endothelial function is affected by ED and hormonal treatment and to fill gaps regarding the effects of PDE5 inhibitors and testosterone therapy on vascular health. Participants are divided into three groups: one group of men with vasculogenic ED receiving daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy, a second group of hypogonadal men receiving testosterone therapy following clinical guidelines, and a third group of men with vasculogenic ED who receive no intervention. Endothelial function is measured using the EndoPAT device at the start of the study and again at 3 and 6 months after treatment begins or baseline for the no-intervention group. Throughout the study, participants undergo assessments of endothelial function by Reactive Hyperemia Index (RHI) using EndoPAT, as well as evaluations of cardiovascular health markers, sexual function scores, and monitoring for adverse events at baseline and at 3 and 6 months follow-ups. The study is non-randomized and open-label, with a total participation duration of 6 months to evaluate changes over time in endothelial and cardiovascular health linked to ED and hormonal therapy.

EndoPAT Device for Endothelial Dysfunction in ED